Opdivo + Yervoy

Active substance nivolumab + ipilimumab
Holder     BMS
Status Running
Indication Treatment of adult patients with unresectable malignant pleural mesothelioma that have progressed after at least one line of treatment, including platinumbased doublet chemotherapy.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 10/08/2022


Last updated on 10/08/2022